Open AccessWhite matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities
Author(s) -
Alber Jessica,
Alladi Suvarna,
Bae HeeJoon,
Barton David A.,
Beckett Laurel A.,
Bell Joanne M.,
Berman Sara E.,
Biessels Geert Jan,
Black Sandra E.,
Bos Isabelle,
Bowman Gene L.,
Brai Emanuele,
Brickman Adam M.,
Callahan Brandy L.,
Corriveau Roderick A.,
Fossati Silvia,
Gottesman Rebecca F.,
Gustafson Deborah R.,
Hachinski Vladimir,
Hayden Kathleen M.,
Helman Alex M.,
Hughes Timothy M.,
Isaacs Jeremy D.,
Jefferson Angela L.,
Johnson Sterling C.,
Kapasi Alifiya,
Kern Silke,
Kwon Jay C.,
Kukolja Juraj,
Lee Athene,
Lockhart Samuel N.,
Murray Anne,
Osborn Katie E.,
Power Melinda C.,
Price Brittani R.,
RhodiusMeester Hanneke F.M.,
Rondeau Jacqueline A.,
Rosen Allyson C.,
Rosene Douglas L.,
Schneider Julie A.,
Scholtzova Henrieta,
Shaaban C. Elizabeth,
Silva Narlon C.B.S.,
Snyder Heather M.,
Swardfager Walter,
Troen Aron M.,
Veluw Susanne J.,
Vemuri Prashanthi,
Wallin Anders,
Wellington Cheryl,
Wilcock Donna M.,
Xie Sharon Xiangwen,
Hainsworth Atticus H.
Publication year - 2019
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1016/j.trci.2019.02.001
Subject(s) - hyperintensity , dementia , psychology , cognitive decline , cognition , disease , magnetic resonance imaging , neuroscience , medicine , radiology
White matter hyperintensities (WMHs) are frequently seen on brain magnetic resonance imaging scans of older people. Usually interpreted clinically as a surrogate for cerebral small vessel disease, WMHs are associated with increased likelihood of cognitive impairment and dementia (including Alzheimer's disease [AD]). WMHs are also seen in cognitively healthy people. In this collaboration of academic, clinical, and pharmaceutical industry perspectives, we identify outstanding questions about WMHs and their relation to cognition, dementia, and AD. What molecular and cellular changes underlie WMHs? What are the neuropathological correlates of WMHs? To what extent are demyelination and inflammation present? Is it helpful to subdivide into periventricular and subcortical WMHs? What do WMHs signify in people diagnosed with AD? What are the risk factors for developing WMHs? What preventive and therapeutic strategies target WMHs? Answering these questions will improve prevention and treatment of WMHs and dementia.